CoreCap Advisors’s abrdn Life Sciences Investors HQL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10.7K Hold
534
﹤0.01% 2044
2026
Q1
$8.69K Hold
534
﹤0.01% 1995
2025
Q4
$8.96K Sell
534
-350
-40% -$5.88K ﹤0.01% 2004
2025
Q3
$13.7K Hold
884
﹤0.01% 1806
2025
Q2
$11.3K Hold
884
﹤0.01% 1820
2025
Q1
$11.2K Hold
884
﹤0.01% 1769
2024
Q4
$11.6K Hold
884
﹤0.01% 1718
2024
Q3
$13.3K Hold
884
﹤0.01% 1703
2024
Q2
$12.5K Hold
884
﹤0.01% 1020
2024
Q1
$12K Buy
+884
New +$12.2K ﹤0.01% 1685
2022
Q4
$9.69K Buy
+682
New +$9.88K ﹤0.01% 1552
2022
Q3
Sell
-559
Closed -$8K 1195
2022
Q2
$8K Buy
+559
New +$8.44K ﹤0.01% 1537
2022
Q1
Sell
-600
Closed -$12K 1204
2021
Q4
$12K Buy
+600
New +$12.1K ﹤0.01% 1491

Other funds holding HQL

CoreCap Advisors's HQL Position: Q2 2026 in Review

CoreCap Advisors held its abrdn Life Sciences Investors (HQL) position steady in Q2 2026 at 534 shares worth $10.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2044.

CoreCap Advisors first reported a position in HQL in Q4 2021 and has held it in 13 quarters since. The position peaked at $13.7K in Q3 2025. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

  • CoreCap Advisors held 534 shares of abrdn Life Sciences Investors worth $10.7K as of Q2 2026.
  • CoreCap Advisors left its abrdn Life Sciences Investors share count unchanged in Q2 2026.
  • abrdn Life Sciences Investors made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2044 holding.
  • CoreCap Advisors first reported a position in abrdn Life Sciences Investors in Q4 2021 and has held it in 13 quarters since.
  • CoreCap Advisors's abrdn Life Sciences Investors position peaked at $13.7K in Q3 2025.
  • 83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.